Molecularly targeted therapeutics for breast cancer

BioDrugs

Volumn 21, Issue 4, 2007, Pages 215-224

  Hussain, Syed A ^a,b   Palmer, Daniel H ^a   Spooner, David ^a   Rea, Daniel W ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FC RECEPTOR; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; LONAFARNIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TIPIFARNIB; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; HORMONAL THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 34547108846     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721040-00002     Document Type: Review

References (63)

1. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004 Jun; 31 Suppl. 1: S149-61
2. Beatson CT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; II: 104-7
3. Beatson CT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; II: 162-5
4. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355 (9217): 1757-70
5. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in 2000 at ages 20-69 years. Lancet 2000; 355: 1822
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): 1687-717
7. Hussain SA, Palmer DH, Moon S, et al. Role of endocrine therapy in metastatic breast cancer: expert review of anti-cancer therapy. Expert Rev Anticancer Ther 2004; 4 (6): 1179-95
8. Ménard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-8
9. Kute T, Lack CM, Willingham M, et al. Development of herceptin resistance in breast cancer cells. Cytometry 2004; 57A: 86-93
10. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27
11. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med 2000; 6: 443-6
12. Spiridon CI, Ghetie MA, Uhr J, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002; 8: 1720-30
13. Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92
15. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26 (4 Suppl. 12): 89-95
16. Pienkowski T, Fumoleau P, Eiermann W, et al. Taxotere, cisplatin and herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 2001; 20: A2030
17. Slamon DJ, Patel R, Northfelt R, et al. Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-neu proto-oncogene a pilot study of the UCLA Network. Proc Am Soc Clin Oncol 2001; 20: A193
18. National Cancer Institute. Combination chemotherapy with or without trastuzumab in treating women with breast cancer [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00005970 [Accessed 2007 Apr 17]
19. Hesnon ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006 Feb 1; 12 (3 Pt 1): 845-53
20. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 Mar 15; 344 (11): 783-92
21. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353 (16): 1673-84
22. Piccart-Gebhart MH, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353 (16): 1659-72
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
24. Zelnak AB, O'Regan RM. Targeting angiogenesis in advanced breast cancer. BioDrugs 2007; 21 (4): 209-14
25. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998 Nov 26; 339 (22): 1609-18
26. Howell A, DeFriend D, Robertson J, et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995 Jan 7; 345 (8941): 29-30
27. Schiff R, Massarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signalling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9 Suppl.: 447-54s
28. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997 Jun; 11 (6): 657-66
29. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998 Mar 17; 95 (6): 2920-5
30. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001 Dec; 7 (12 Suppl.): 4429-35s
31. Nicholson RI, Gee JM, Barrow D, et al. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 1999 Nov 16-19; Washington, DC
32. Lupu R, Cardillo M, Cho C, et al. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 1996; 38 (1): 57-66
33. Osborne CK, Bardou V-J, Hilsenbeck SG, et al. The estrogen receptor coactivator AIB1 (SRC3) in combination with HER-2 is a prognostic and predictive marker in patients with breast cancer. Proc Am Soc Clin Oncol 2002; 21: A129
34. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000 Feb; 82 (3): 501-13
35. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031-7
36. Mauro MJ, O'Dwyer M, Heinrich MC, et al. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002 Jan 1; 20 (1): 325-34
37. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002 May 1; 20 (9): 2240-50
38. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000 May; 6 (5): 2053-63
39. Fukuoka M, Yano S, Giaccone G. Final results from a phase II trial of ZD1839 (Iressa) in patients with advanced non-small cell lung cancer (IDEAL-1) [abstract no. 1188]. Proc Am Soc Clin Oncol 2002; 21: 298a
40. Albain K, Elledge R, Gradishar WJ, et al. Open-label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76: A20
41. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: A23
42. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76: A445
43. von Minckwitz G, Jonat W, Fasching P, et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005 Jan; 89 (2): 165-72
44. US Food and Drug Administration. Gefitinib (marketed as Iressa) information [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/ gefitinib/default.htm [Accessed 2007 Jun 21]
45. Gutteridge E, Gee JM, Nicholson RI, et al. Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer. J Clin Oncol 2004; 22 (14S): 648
46. Agrawal A, Gutteridge E, Gee JMW, et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005; 12 Suppl. 1: S135-44
47. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002 Jun; 29 (3 Suppl. 11): 4-10
48. Allen LF, Lenehan PF, Eiseman IA, et al. Potential benefits of the irreversible panerbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002 Jun; 29 (3 Suppl. 11): 11-21
49. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 2005; 23 (16 Suppl Pt I of II): 3046
50. Geyer CE, Forster JK, Cameron D, et al. Scientific special session: lapatinib in trastuzumab resistant breast cancer. ASCO Annual Meeting; 2006 Jun 2-6; Atlanta (GA)
51. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995 Jul; 35 (1): 133-44
52. Kelland LR, Smith V, Valenti M, et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001 Nov; 7 (11): 3544-50
53. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003 Jul 1; 21 (13): 2492-9
54. Johnston SRD, Hickish T, Ellis PA, et al. Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: relationship with tumour phenotype. Breast Cancer Res Treat 2000; 64; 32: A28
55. Johnston SRD, Head J, Valenti M, et al. Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo. Breast Cancer Res Treat 2002; 76: A245
56. Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46 (5): 387-93
57. Emory University. Interaction of docetaxel and lonafarnib in patients with advanced cancer [online]. Available from URL: http://www.clinicaltrials. gov/ct/show/NCT00288444?order=1 [Accessed 2007 Apr 17]
58. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001 Sep; 8 (3): 249-58
59. O'Byrne KJ, Dobbs N, Propper DJ, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999 Mar; 79 (9-10): 1413-8
60. Ingle JN, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999 Mar 15; 85 (6): 1284-92
61. Chernicky CL, Tan H, Yi L, et al. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 2002 Apr; 55 (2): 102-9
62. Yee D. The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 2002 Jun; 29 (3 Suppl. 11): 86-95
63. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005; 12 (2): 73-85